119 related articles for article (PubMed ID: 38864848)
21. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
22. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
[TBL] [Abstract][Full Text] [Related]
23. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
24. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
25. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
[TBL] [Abstract][Full Text] [Related]
26. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
27. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.
Wu L; Chen J; Cai R; Wang X; Liu Y; Zheng Q; Li L
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345104
[TBL] [Abstract][Full Text] [Related]
28. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.
Bove C; Arcangeli S; Falcone L; Camisa B; El Khoury R; Greco B; De Lucia A; Bergamini A; Bondanza A; Ciceri F; Bonini C; Casucci M
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593069
[TBL] [Abstract][Full Text] [Related]
29. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
30. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia.
Zhao X; Yang J; Zhang X; Lu XA; Xiong M; Zhang J; Zhou X; Qi F; He T; Ding Y; Hu X; De Smet F; Lu P; Huang X
Mol Ther Oncolytics; 2020 Sep; 18():272-281. PubMed ID: 32728615
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.
Weinstein B; Muresan B; Solano S; de Macedo AV; Lee Y; Su YC; Ahn Y; Henriquez G; Camargo C; Kim GJ; Carpenter DO
Innov Pharm; 2021; 12(4):. PubMed ID: 36033121
[TBL] [Abstract][Full Text] [Related]
33. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
34. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
35. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
36. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
37. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
38. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
39. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
[TBL] [Abstract][Full Text] [Related]
40. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.
Riberdy JM; Zhou S; Zheng F; Kim YI; Moore J; Vaidya A; Throm RE; Sykes A; Sahr N; Bonifant CL; Ryu B; Gottschalk S; Velasquez MP
Mol Ther Methods Clin Dev; 2020 Sep; 18():571-581. PubMed ID: 32775492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]